4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,660,500 | -34.1% | 1,465,868 | -6.5% | 0.00% | -33.3% |
| Q2 2023 | $28,329,404 | -5.4% | 1,567,759 | -10.0% | 0.00% | 0.0% |
| Q1 2023 | $29,942,867 | -7.6% | 1,741,877 | +19.4% | 0.00% | -25.0% |
| Q4 2022 | $32,394,883 | +99.3% | 1,458,572 | -27.8% | 0.00% | +100.0% |
| Q3 2022 | $16,252,000 | +643.8% | 2,021,573 | +545.8% | 0.00% | – |
| Q2 2022 | $2,185,000 | -65.6% | 313,039 | -25.5% | 0.00% | -100.0% |
| Q1 2022 | $6,351,000 | -33.3% | 420,036 | -3.2% | 0.00% | 0.0% |
| Q4 2021 | $9,523,000 | -4.2% | 434,078 | +17.8% | 0.00% | 0.0% |
| Q3 2021 | $9,937,000 | -4.2% | 368,451 | -14.5% | 0.00% | 0.0% |
| Q2 2021 | $10,374,000 | -12.1% | 430,787 | +58.3% | 0.00% | -50.0% |
| Q1 2021 | $11,805,000 | +15.9% | 272,146 | +10.8% | 0.00% | 0.0% |
| Q4 2020 | $10,184,000 | – | 245,705 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |